$BCDA
BioCardia, Inc.

2022 Q3 Form 10-Q Financial Statement

#000143774922019788 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $212.0K $974.0K $60.00K
YoY Change -74.18% 1311.59% 30.43%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.128M $1.166M $1.201M
YoY Change -12.49% -2.51% 2.04%
% of Gross Profit
Research & Development $2.144M $2.304M $2.186M
YoY Change -4.29% -2.46% 18.74%
% of Gross Profit
Depreciation & Amortization $29.00K $16.00K $16.00K
YoY Change 93.33% 0.0% 14.29%
% of Gross Profit
Operating Expenses $3.272M $3.470M $3.387M
YoY Change -7.28% -2.47% 12.23%
Operating Profit -$3.060M -$2.496M -$3.327M
YoY Change 13.0% -28.46% 11.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.000K -$1.000K $2.000K
YoY Change 50.0% -150.0% -33.33%
Pretax Income -$3.057M -$2.497M -$3.325M
YoY Change 12.97% -28.39% 11.95%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.057M -$2.497M -$3.325M
YoY Change 12.97% -28.39% 11.99%
Net Earnings / Revenue -1441.98% -256.37% -5541.67%
Basic Earnings Per Share -$0.17 -$0.14 -$0.19
Diluted Earnings Per Share -$171.3K -$141.5K -$194.8K
COMMON SHARES
Basic Shares Outstanding 17.76M 17.65M 17.07M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.667M $8.614M $9.930M
YoY Change -58.04% -53.55% -53.81%
Cash & Equivalents $6.667M $8.600M $9.900M
Short-Term Investments
Other Short-Term Assets $187.0K $327.0K $405.0K
YoY Change -47.77% -19.66% 19.12%
Inventory
Prepaid Expenses
Receivables $300.0K $211.0K $326.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.154M $9.152M $10.66M
YoY Change -57.93% -53.64% -52.95%
LONG-TERM ASSETS
Property, Plant & Equipment $189.0K $204.0K $195.0K
YoY Change 8.0% 10.87% 18.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $172.0K $171.0K $172.0K
YoY Change 224.53%
Total Long-Term Assets $2.025M $2.114M $2.179M
YoY Change 525.0% 343.19% 235.75%
TOTAL ASSETS
Total Short-Term Assets $7.154M $9.152M $10.66M
Total Long-Term Assets $2.025M $2.114M $2.179M
Total Assets $9.179M $11.27M $12.84M
YoY Change -47.03% -44.28% -44.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $887.0K $999.0K $764.0K
YoY Change 4.85% 2.99% -10.12%
Accrued Expenses $115.0K $29.00K $34.00K
YoY Change 45.57% -17.14% -85.83%
Deferred Revenue $378.0K $0.00 $948.0K
YoY Change -57.34% -100.0% -19.66%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.684M $3.054M $3.913M
YoY Change -5.97% -32.81% -17.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.398M $1.478M $1.558M
YoY Change
Total Long-Term Liabilities $1.398M $1.478M $1.558M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.684M $3.054M $3.913M
Total Long-Term Liabilities $1.398M $1.478M $1.558M
Total Liabilities $5.082M $4.532M $5.471M
YoY Change 29.71% -0.29% 15.28%
SHAREHOLDERS EQUITY
Retained Earnings -$137.6M -$134.5M -$132.0M
YoY Change 9.88% 9.8% 10.88%
Common Stock $18.00K $18.00K $17.00K
YoY Change 5.88% 5.88% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.097M $6.734M $7.369M
YoY Change
Total Liabilities & Shareholders Equity $9.179M $11.27M $12.84M
YoY Change -47.03% -44.28% -44.91%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$3.057M -$2.497M -$3.325M
YoY Change 12.97% -28.39% 11.99%
Depreciation, Depletion And Amortization $29.00K $16.00K $16.00K
YoY Change 93.33% 0.0% 14.29%
Cash From Operating Activities -$2.006M -$2.645M -$2.913M
YoY Change -24.1% -7.78% 54.7%
INVESTING ACTIVITIES
Capital Expenditures -$14.00K -$25.00K $29.00K
YoY Change -30.0% 0.0% 7.41%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$14.00K -$25.00K -$29.00K
YoY Change -30.0% 0.0% 7.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 73.00K 1.354M $0.00
YoY Change 812.5% -2007.04% -100.0%
NET CHANGE
Cash From Operating Activities -2.006M -2.645M -$2.913M
Cash From Investing Activities -14.00K -25.00K -$29.00K
Cash From Financing Activities 73.00K 1.354M $0.00
Net Change In Cash -1.947M -1.316M -$2.942M
YoY Change -26.67% -55.6% -3196.84%
FREE CASH FLOW
Cash From Operating Activities -$2.006M -$2.645M -$2.913M
Capital Expenditures -$14.00K -$25.00K $29.00K
Free Cash Flow -$1.992M -$2.620M -$2.942M
YoY Change -24.06% -7.84% 54.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000925741
dei Entity Registrant Name
EntityRegistrantName
BioCardia, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
13000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
22000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17758194
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17758194
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16871265
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16871265
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
67000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
232000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-21419
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
23-2753988
dei Entity Address Address Line1
EntityAddressAddressLine1
320 Soquel Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94085
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
226-0120
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17758194
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8614000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12872000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
211000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
147000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
327000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
462000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
9152000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
13481000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
204000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
182000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1739000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1883000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
171000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
172000 usd
CY2022Q2 us-gaap Assets
Assets
11266000 usd
CY2021Q4 us-gaap Assets
Assets
15718000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
974000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
69000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1034000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
115000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
999000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
507000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2304000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2362000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4490000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4203000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1166000 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1196000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2367000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2373000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
3470000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
3558000 usd
us-gaap Costs And Expenses
CostsAndExpenses
6857000 usd
us-gaap Costs And Expenses
CostsAndExpenses
6576000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2496000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3489000 usd
CY2022Q2 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1763000 usd
CY2021Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2121000 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
847000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
292000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
237000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3054000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3712000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1478000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1631000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
4532000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
5343000 usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
18000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
17000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
141235000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139055000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134519000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128697000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
6734000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10375000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11266000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15718000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5823000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6461000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2497000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3487000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5822000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6456000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-48000 usd
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
-0 usd
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
-56000 usd
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17651892
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17047411
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17360598
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16809661
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
19176000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1934000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
416000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2969000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
18562000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
384000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
214000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3487000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
15673000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10375000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
319000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3325000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7369000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
271000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1287000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
304000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2497000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
6734000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5822000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6456000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
30000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
144000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
274000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
623000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
800000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
64000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-136000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
425000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
210000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-87000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-149000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-847000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
734000 usd
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-98000 usd
bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-298000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5558000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4748000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1519000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2001000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
165000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
67000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1354000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1939000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4258000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2864000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12872000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21407000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8614000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18543000 usd
us-gaap Stock Issued1
StockIssued1
67000 usd
us-gaap Stock Issued1
StockIssued1
66000 usd
bcda Issuance Of Restricted Stock Units In Lieu Of Cash Compensation
IssuanceOfRestrictedStockUnitsInLieuOfCashCompensation
401000 usd
bcda Issuance Of Restricted Stock Units In Lieu Of Cash Compensation
IssuanceOfRestrictedStockUnitsInLieuOfCashCompensation
393000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134500000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8600000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
229000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
471000 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
773000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
719000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
569000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
537000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
204000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
182000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
16000 usd
us-gaap Depreciation
Depreciation
32000 usd
CY2021Q2 us-gaap Depreciation
Depreciation
16000 usd
us-gaap Depreciation
Depreciation
30000 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
120000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
241000 usd
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
301000 usd
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
76000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
173000 usd
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
162000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
324000 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M2D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1074 pure
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
485000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
499000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
514000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
44000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2242000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
472000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1770000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
240000 usd
CY2022Q2 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
734000 usd
CY2021Q4 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
861000 usd
CY2022Q2 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
301000 usd
CY2021Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
334000 usd
CY2022Q2 bcda Grant Liability Current
GrantLiabilityCurrent
562000 usd
CY2021Q4 bcda Grant Liability Current
GrantLiabilityCurrent
590000 usd
CY2022Q2 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
90000 usd
CY2021Q4 bcda Customer Deposit Liabilities Current
CustomerDepositLiabilitiesCurrent
96000 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
47000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 usd
CY2022Q2 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1763000 usd
CY2021Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2121000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
955545
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2424724
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
bcda Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
0
bcda Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
0
bcda Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
-0
bcda Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
0
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2424724
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
304000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
384000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
623000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
800000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1649686
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.00
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
504949
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.53
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
90688
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3111
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
9.55
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2060836
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4488294
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4115251
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">12</em>)</b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Contingencies and Uncertainties</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt; text-align: justify;"><i>Contingencies</i> - The Company <em style="font: inherit;"> may </em>be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management is <em style="font: inherit;">not</em> aware of any current legal or administrative proceedings that are likely to have an adverse effect on the Company’s business, financial position, results of operations, or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 54pt;"><i>Uncertainties</i> - The results for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>are <em style="font: inherit;">not</em> necessarily indicative of the results to be expected for the year ending <em style="font: inherit;"> December 31, 2022 </em>or for any other interim period or for any other future year, particularly in light of the novel coronavirus pandemic, or COVID-<em style="font: inherit;">19,</em> and its impact on domestic and global economies. While the impact of the COVID-<em style="font: inherit;">19</em> pandemic did <em style="font: inherit;">not</em> have a material adverse effect on our financial position or results of operations for the periods presented, the governmental actions and similar actions that <em style="font: inherit;"> may </em>be enacted in the future, and the widespread economic disruption arising from the pandemic, have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-<em style="font: inherit;">19</em> pandemic, which <em style="font: inherit;"> may </em>require adjustments to the Company’s estimates and assumptions in the future.</p>

Files In Submission

Name View Source Status
0001437749-22-019788-index-headers.html Edgar Link pending
0001437749-22-019788-index.html Edgar Link pending
0001437749-22-019788.txt Edgar Link pending
0001437749-22-019788-xbrl.zip Edgar Link pending
bcda-20220630.xsd Edgar Link pending
bcda20220630_10q.htm Edgar Link pending
ex_405706.htm Edgar Link pending
ex_405707.htm Edgar Link pending
ex_405708.htm Edgar Link pending
ex_405709.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
bcda-20220630_def.xml Edgar Link unprocessable
bcda-20220630_pre.xml Edgar Link unprocessable
bcda-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcda20220630_10q_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcda-20220630_cal.xml Edgar Link unprocessable